BioStar Capital

About

Portfolio · 3

CathWorks

Noninvasive FFR Measurements for Coronary Interventions

1 round $15.8M committed Latest: 2017-10

V-Wave

Miniature Shunt for Treating Congestive Heart Failure

1 round $28.0M committed Latest: 2016-01

Newpace

Subcutaneous Implantable Cardioverter Defibrillator

1 round $2.0M committed Latest: 2015-08

Investment activity

2 portfolio exits on record.

Q&A

What is BioStar Capital's primary investment focus by sector?

BioStar Capital primarily focuses on the Health Tech & Life Sciences sector, with all four of its portfolio companies operating in this area.

Can you name some of BioStar Capital's notable exits?

BioStar Capital has seen two significant exits recently: CathWorks was acquired by Medtronic for $585M in February 2026, and V-Wave was acquired by Johnson & Johnson for $600M in August 2024.

Which portfolio companies has BioStar Capital invested in?

BioStar Capital's portfolio includes companies such as Angioslide, which develops embolic capture angioplasty devices, and CathWorks, known for noninvasive FFR measurements for coronary interventions.

What was the most recent exit for BioStar Capital?

BioStar Capital's most recent exit was CathWorks, which was acquired by Medtronic for $585M in February 2026.

What was the acquisition value for V-Wave, a BioStar Capital portfolio company?

V-Wave, a BioStar Capital portfolio company, was acquired by Johnson & Johnson for $600M in August 2024.

What is the typical investment range for BioStar Capital?

BioStar Capital's investment range is between $2M and $28M.